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Human and simian immunodeficiency
viruses (HIV and SIVs) contain several
auxiliary genes not found in other retro-
viruses. These genes are thought to be
functionally important for optimal viral
replication and persistence in infected
individuals. Primate lentiviruses can be
classified by the composition of these
accessory genes. While viruses of the
HIV type1 (HIV-1) group have vif, vpr,
vpu, and nef genes, those of the HIV-2
group carry vif, vpx, vpr, and nef genes
(Fujita et al., 2010). Vpx protein encoded
by the vpx gene is unique to non-HIV-1
viruses, and is essential for viral repli-
cation in macrophages in contrast to its
structural paralog Vpr (Fujita et al., 2010).
The most outstanding sequence feature
to distinguish Vpx from Vpr is the pres-
ence of poly-proline motif (PPM) at its
C-terminal region.We have recently shown,
by in vitro and in vivo assay systems, that
the PPM in HIV-2 Vpx is critical for its
efficient translation (Miyake et al., 2014).
Although PPM consisting of seven con-
secutive prolines has been demonstrated
to be required for efficient HIV-2 Vpx
translation, thereby acquiring viral infec-
tivity in macrophages, the effects of PPM
mutations on the degradation of Vpx
in cells was not formally analyzed as
yet (Fujita et al., 2008; Miyake et al.,
2014). Therefore, in this study, we asked
whether the PPM plays a role in keep-
ing away from proteasomal and/or lyso-
somal degradation (Figure 1). In order to
assess this, we used various expression
plasmids for HIV-2 Vpx (pEF-Fvpx series)
described in a previous study (Miyake
et al., 2014): wild-type (WT) plasmid
has the vpx gene derived from HIV-2
GL-AN clone (Kawamura et al., 1994);
mutants 103/4A and 106/4A have four
consecutive alanine-substitutions at the
site of P103-P106 and P106-P109, respec-
tively, and have been shown to express a
low/minimum level of mutant Vpx pro-
teins in cells (Figure 1A); a negative con-
trol is a frame-shift mutant pEF-FxSt that
lacks Vpx expression (Vpx).
Various expression plasmids were
transfected into human 293T cells
(Lebkowski et al., 1985) as described
FIGURE 1 | Steady-state levels of various Vpx-PPM mutants in cells as monitored by Western
blotting. (A) Structure of the FLAG-tagged HIV-2 GL-AN Vpx construct. Numerals above the schema
represent amino acid numbers of the Vpx protein. Positions of lysine and glutamine residues
mutated are indicated. (B) Expression of Vpx-PPM mutants in the presence of a proteasome
inhibitor MG-132 or a lysosome inhibitor Bafilomycin A1. (C) Expression of lysine-mutants with or
without 106/4A mutation. (D) Expression of Q76A mutants with or without 106/4A mutation. For
(B) to (D) experiments, 293T cells were transfected with the plasmids indicated, and harvested for
Western blotting 24 h later. To examine lysosomal and proteasomal degradation processes (B),
100 nM of BafilomycinA1 (Yoshimori et al., 1991) and 7.5µM of MG-132 (McCulley and Ratner,
2012) were added at 5 and 16 h post-transfection, respectively. WT, pEF-Fvpx; Vpx, pEF-FxSt.
before (Adachi et al., 1986), and the
amounts of WT and mutant Vpx proteins
produced in cells in the absence or pres-
ence of a proteasome inhibitor MG-132
(Fujita et al., 2004; McCulley and Ratner,
2012) were comparatively examined by
Western blotting (Miyake et al., 2014). A
drastic reduction in Vpx expression was
observed for mutants 103/4A and 106/4A,
106/4A in particular, both in the absence
www.frontiersin.org January 2014 | Volume 5 | Article 24 | 1
Miyake et al. PPM of HIV-2 Vpx
and presence of MG-132 (Figure 1B).
These results showed that neither of these
mutants could be rescued with MG-
132, suggesting no involvement of the
PPM in the proteasome-mediated degra-
dation. Similarly, a lysosome inhibitor
Bafilomycin A1 (Yoshimori et al., 1991)
did not affect much the level of 103/4A and
106/4A in transfected 293T cells, although
a small increase was observed for both
mutants (Figure 1B). These results sug-
gested that the low expression level of these
PPM mutants may not be attributable to
the lysosomal degradation.
Proteasomal degradation is generally
triggered by the polyubiquitin modifi-
cation of lysine residues in a protein.
There are three lysines in the Vpx of HIV-
2 GL-AN clone (Khamsri et al., 2006)
(Figure 1A). We generated several clones
carrying mutations in these residues.
Furthermore, we focused on the 76th glu-
tamine residue (Figure 1A). This amino
acid has been reported to interact with
DCAF1 for formation of Cullin4-based
E3 ubiquitin ligase complex to degrade
an anti-HIV restriction factor SAMHD1
(Hrecka et al., 2011; Laguette et al.,
2011) by proteasome (Le Rouzic et al.,
2007; Srivastava et al., 2008). Mutants
K68R, K77R, K84R, and Q76A with or
without the 106/4A mutation were con-
structed as described previously (Miyake
et al., 2014) (Figure 1A), and examined
for their expression in transfected cells
(Figures 1C,D). As shown in Figure 1C,
only one clone with K84R and 106/4A
mutations showed a slight enhancement
in agreement with a previous report
(Srivastava et al., 2008). Moreover, no
significant effect was observed for a
mutant carrying Q76A and 106/4A muta-
tions (Figure 1D). These results also
suggested that PPM may not be asso-
ciated with the proteasome-mediated
degradation.
In total, proteasomal or lysosomal
degradation does not account for the
extremely low expression level of Vpx
exhibited by the PPM mutants. This is
consistent with our previous conclusion
that PPM is critical for efficient translation
of Vpx (Miyake et al., 2014). Molecular
mechanism by which PPM enhances Vpx
translation to a remarkable extent needs to
be determined.
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